nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Mycophenolate mofetil—psoriasis	0.163	0.288	CbGbCtD
Eprosartan—ABCC2—Cyclosporine—psoriasis	0.124	0.219	CbGbCtD
Eprosartan—ABCC2—Dexamethasone—psoriasis	0.0813	0.144	CbGbCtD
Eprosartan—ABCC2—Methotrexate—psoriasis	0.0654	0.116	CbGbCtD
Eprosartan—CYP2C9—Cholecalciferol—psoriasis	0.0631	0.112	CbGbCtD
Eprosartan—CYP2C9—Cyclosporine—psoriasis	0.0415	0.0734	CbGbCtD
Eprosartan—CYP2C9—Dexamethasone—psoriasis	0.0273	0.0483	CbGbCtD
Eprosartan—AGTR1—Allograft Rejection—IL22—psoriasis	0.00435	0.135	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—REN—psoriasis	0.00371	0.115	CbGpPWpGaD
Eprosartan—Losartan—ACE—psoriasis	0.00289	1	CrCbGaD
Eprosartan—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.0024	0.0744	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—ACE—psoriasis	0.00232	0.0719	CbGpPWpGaD
Eprosartan—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00149	0.0461	CbGpPWpGaD
Eprosartan—ABCC2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00112	0.0348	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—HLA-C—psoriasis	0.000824	0.0256	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL13—psoriasis	0.000819	0.0254	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL17A—psoriasis	0.000753	0.0234	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL12B—psoriasis	0.0007	0.0217	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—HLA-E—psoriasis	0.000684	0.0212	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000663	0.0206	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000645	0.02	CbGpPWpGaD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000617	0.0191	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000609	0.0189	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000514	0.0159	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL10—psoriasis	0.000512	0.0159	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—HCAR2—psoriasis	0.000505	0.0157	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.0005	0.0155	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL4—psoriasis	0.000498	0.0155	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—HLA-B—psoriasis	0.000487	0.0151	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—HLA-A—psoriasis	0.000451	0.014	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00045	0.014	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—HLA-DRB1—psoriasis	0.000412	0.0128	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NFKB1—psoriasis	0.000361	0.0112	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000345	0.0107	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFA—psoriasis	0.000337	0.0104	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IFNG—psoriasis	0.000301	0.00934	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—HCAR2—psoriasis	0.000286	0.00886	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000283	0.00879	CbGpPWpGaD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriasis	0.000281	0.00872	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—CXCL8—psoriasis	0.00028	0.00869	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000266	0.00824	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCL20—psoriasis	0.000262	0.00814	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000262	0.00813	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HCAR2—psoriasis	0.000259	0.00805	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—VEGFA—psoriasis	0.000227	0.00706	CbGpPWpGaD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000197	0.00613	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TNF—psoriasis	0.000195	0.00605	CbGpPWpGaD
Eprosartan—Constipation—Cyclosporine—psoriasis	0.000193	0.000483	CcSEcCtD
Eprosartan—Dry mouth—Triamcinolone—psoriasis	0.000193	0.000482	CcSEcCtD
Eprosartan—Renal failure—Methotrexate—psoriasis	0.000192	0.000481	CcSEcCtD
Eprosartan—Angioedema—Betamethasone—psoriasis	0.000192	0.00048	CcSEcCtD
Eprosartan—Angioedema—Dexamethasone—psoriasis	0.000192	0.00048	CcSEcCtD
Eprosartan—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000191	0.000479	CcSEcCtD
Eprosartan—Anorexia—Hydrocortisone—psoriasis	0.000191	0.000478	CcSEcCtD
Eprosartan—Diarrhoea—Mycophenolic acid—psoriasis	0.000191	0.000477	CcSEcCtD
Eprosartan—Conjunctivitis—Methotrexate—psoriasis	0.00019	0.000475	CcSEcCtD
Eprosartan—Malaise—Betamethasone—psoriasis	0.000189	0.000473	CcSEcCtD
Eprosartan—Malaise—Dexamethasone—psoriasis	0.000189	0.000473	CcSEcCtD
Eprosartan—Vertigo—Betamethasone—psoriasis	0.000189	0.000472	CcSEcCtD
Eprosartan—Vertigo—Dexamethasone—psoriasis	0.000189	0.000472	CcSEcCtD
Eprosartan—Syncope—Dexamethasone—psoriasis	0.000188	0.000471	CcSEcCtD
Eprosartan—Syncope—Betamethasone—psoriasis	0.000188	0.000471	CcSEcCtD
Eprosartan—Pain—Mycophenolate mofetil—psoriasis	0.000188	0.000471	CcSEcCtD
Eprosartan—Constipation—Mycophenolate mofetil—psoriasis	0.000188	0.000471	CcSEcCtD
Eprosartan—Hypotension—Hydrocortisone—psoriasis	0.000187	0.000469	CcSEcCtD
Eprosartan—Haematuria—Methotrexate—psoriasis	0.000186	0.000466	CcSEcCtD
Eprosartan—Feeling abnormal—Cyclosporine—psoriasis	0.000186	0.000465	CcSEcCtD
Eprosartan—Shock—Triamcinolone—psoriasis	0.000186	0.000465	CcSEcCtD
Eprosartan—Insomnia—Prednisolone—psoriasis	0.000186	0.000464	CcSEcCtD
Eprosartan—Gastrointestinal pain—Cyclosporine—psoriasis	0.000184	0.000461	CcSEcCtD
Eprosartan—Loss of consciousness—Betamethasone—psoriasis	0.000184	0.000461	CcSEcCtD
Eprosartan—Loss of consciousness—Dexamethasone—psoriasis	0.000184	0.000461	CcSEcCtD
Eprosartan—Dizziness—Mycophenolic acid—psoriasis	0.000184	0.000461	CcSEcCtD
Eprosartan—Epistaxis—Methotrexate—psoriasis	0.000184	0.000461	CcSEcCtD
Eprosartan—Paraesthesia—Prednisolone—psoriasis	0.000184	0.000461	CcSEcCtD
Eprosartan—Tachycardia—Triamcinolone—psoriasis	0.000184	0.000461	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000183	0.000457	CcSEcCtD
Eprosartan—Hyperhidrosis—Triamcinolone—psoriasis	0.000182	0.000457	CcSEcCtD
Eprosartan—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000181	0.000454	CcSEcCtD
Eprosartan—Insomnia—Hydrocortisone—psoriasis	0.000181	0.000454	CcSEcCtD
Eprosartan—Paraesthesia—Hydrocortisone—psoriasis	0.00018	0.00045	CcSEcCtD
Eprosartan—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00018	0.00045	CcSEcCtD
Eprosartan—Urticaria—Cyclosporine—psoriasis	0.000179	0.000448	CcSEcCtD
Eprosartan—Myalgia—Dexamethasone—psoriasis	0.000179	0.000447	CcSEcCtD
Eprosartan—Myalgia—Betamethasone—psoriasis	0.000179	0.000447	CcSEcCtD
Eprosartan—Abdominal pain—Cyclosporine—psoriasis	0.000178	0.000446	CcSEcCtD
Eprosartan—Body temperature increased—Cyclosporine—psoriasis	0.000178	0.000446	CcSEcCtD
Eprosartan—Anxiety—Dexamethasone—psoriasis	0.000178	0.000445	CcSEcCtD
Eprosartan—Anxiety—Betamethasone—psoriasis	0.000178	0.000445	CcSEcCtD
Eprosartan—Vomiting—Mycophenolic acid—psoriasis	0.000177	0.000444	CcSEcCtD
Eprosartan—Discomfort—Betamethasone—psoriasis	0.000177	0.000442	CcSEcCtD
Eprosartan—Discomfort—Dexamethasone—psoriasis	0.000177	0.000442	CcSEcCtD
Eprosartan—Dyspepsia—Hydrocortisone—psoriasis	0.000176	0.000441	CcSEcCtD
Eprosartan—Rash—Mycophenolic acid—psoriasis	0.000176	0.00044	CcSEcCtD
Eprosartan—Dermatitis—Mycophenolic acid—psoriasis	0.000176	0.000439	CcSEcCtD
Eprosartan—Pain—Prednisolone—psoriasis	0.000176	0.000439	CcSEcCtD
Eprosartan—Urticaria—Mycophenolate mofetil—psoriasis	0.000175	0.000437	CcSEcCtD
Eprosartan—Headache—Mycophenolic acid—psoriasis	0.000175	0.000437	CcSEcCtD
Eprosartan—Decreased appetite—Hydrocortisone—psoriasis	0.000174	0.000436	CcSEcCtD
Eprosartan—Pharyngitis—Methotrexate—psoriasis	0.000174	0.000436	CcSEcCtD
Eprosartan—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000174	0.000435	CcSEcCtD
Eprosartan—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000174	0.000435	CcSEcCtD
Eprosartan—Fatigue—Hydrocortisone—psoriasis	0.000173	0.000432	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000172	0.00043	CcSEcCtD
Eprosartan—Pain—Hydrocortisone—psoriasis	0.000171	0.000429	CcSEcCtD
Eprosartan—Insomnia—Triamcinolone—psoriasis	0.000171	0.000427	CcSEcCtD
Eprosartan—Ill-defined disorder—Prednisone—psoriasis	0.00017	0.000424	CcSEcCtD
Eprosartan—Paraesthesia—Triamcinolone—psoriasis	0.000169	0.000424	CcSEcCtD
Eprosartan—Feeling abnormal—Prednisolone—psoriasis	0.000169	0.000423	CcSEcCtD
Eprosartan—Visual impairment—Methotrexate—psoriasis	0.000169	0.000423	CcSEcCtD
Eprosartan—Shock—Betamethasone—psoriasis	0.000169	0.000422	CcSEcCtD
Eprosartan—Shock—Dexamethasone—psoriasis	0.000169	0.000422	CcSEcCtD
Eprosartan—Dyspnoea—Triamcinolone—psoriasis	0.000168	0.000421	CcSEcCtD
Eprosartan—Thrombocytopenia—Betamethasone—psoriasis	0.000168	0.00042	CcSEcCtD
Eprosartan—Thrombocytopenia—Dexamethasone—psoriasis	0.000168	0.00042	CcSEcCtD
Eprosartan—Tachycardia—Dexamethasone—psoriasis	0.000167	0.000418	CcSEcCtD
Eprosartan—Tachycardia—Betamethasone—psoriasis	0.000167	0.000418	CcSEcCtD
Eprosartan—Angioedema—Prednisone—psoriasis	0.000167	0.000418	CcSEcCtD
Eprosartan—Hypersensitivity—Cyclosporine—psoriasis	0.000166	0.000416	CcSEcCtD
Eprosartan—Dyspepsia—Triamcinolone—psoriasis	0.000166	0.000416	CcSEcCtD
Eprosartan—Nausea—Mycophenolic acid—psoriasis	0.000166	0.000414	CcSEcCtD
Eprosartan—Hyperhidrosis—Dexamethasone—psoriasis	0.000166	0.000414	CcSEcCtD
Eprosartan—Hyperhidrosis—Betamethasone—psoriasis	0.000166	0.000414	CcSEcCtD
Eprosartan—Feeling abnormal—Hydrocortisone—psoriasis	0.000165	0.000413	CcSEcCtD
Eprosartan—Malaise—Prednisone—psoriasis	0.000165	0.000412	CcSEcCtD
Eprosartan—Vertigo—Prednisone—psoriasis	0.000164	0.000411	CcSEcCtD
Eprosartan—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000164	0.00041	CcSEcCtD
Eprosartan—Syncope—Prednisone—psoriasis	0.000164	0.00041	CcSEcCtD
Eprosartan—Tinnitus—Methotrexate—psoriasis	0.000164	0.000409	CcSEcCtD
Eprosartan—Anorexia—Dexamethasone—psoriasis	0.000163	0.000408	CcSEcCtD
Eprosartan—Anorexia—Betamethasone—psoriasis	0.000163	0.000408	CcSEcCtD
Eprosartan—Urticaria—Prednisolone—psoriasis	0.000163	0.000408	CcSEcCtD
Eprosartan—Fatigue—Triamcinolone—psoriasis	0.000163	0.000407	CcSEcCtD
Eprosartan—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000162	0.000406	CcSEcCtD
Eprosartan—Asthenia—Cyclosporine—psoriasis	0.000162	0.000405	CcSEcCtD
Eprosartan—Pain—Triamcinolone—psoriasis	0.000161	0.000404	CcSEcCtD
Eprosartan—Loss of consciousness—Prednisone—psoriasis	0.000161	0.000402	CcSEcCtD
Eprosartan—Hypotension—Betamethasone—psoriasis	0.00016	0.0004	CcSEcCtD
Eprosartan—Hypotension—Dexamethasone—psoriasis	0.00016	0.0004	CcSEcCtD
Eprosartan—Pruritus—Cyclosporine—psoriasis	0.00016	0.000399	CcSEcCtD
Eprosartan—Urticaria—Hydrocortisone—psoriasis	0.000159	0.000398	CcSEcCtD
Eprosartan—Abdominal pain—Hydrocortisone—psoriasis	0.000158	0.000396	CcSEcCtD
Eprosartan—Body temperature increased—Hydrocortisone—psoriasis	0.000158	0.000396	CcSEcCtD
Eprosartan—Asthenia—Mycophenolate mofetil—psoriasis	0.000158	0.000395	CcSEcCtD
Eprosartan—Chills—Methotrexate—psoriasis	0.000157	0.000394	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000156	0.00039	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000156	0.00039	CcSEcCtD
Eprosartan—Pruritus—Mycophenolate mofetil—psoriasis	0.000156	0.000389	CcSEcCtD
Eprosartan—Myalgia—Prednisone—psoriasis	0.000156	0.000389	CcSEcCtD
Eprosartan—Arthralgia—Prednisone—psoriasis	0.000156	0.000389	CcSEcCtD
Eprosartan—Feeling abnormal—Triamcinolone—psoriasis	0.000156	0.000389	CcSEcCtD
Eprosartan—Anxiety—Prednisone—psoriasis	0.000155	0.000388	CcSEcCtD
Eprosartan—Insomnia—Betamethasone—psoriasis	0.000155	0.000388	CcSEcCtD
Eprosartan—Insomnia—Dexamethasone—psoriasis	0.000155	0.000388	CcSEcCtD
Eprosartan—Diarrhoea—Cyclosporine—psoriasis	0.000154	0.000386	CcSEcCtD
Eprosartan—Paraesthesia—Betamethasone—psoriasis	0.000154	0.000385	CcSEcCtD
Eprosartan—Paraesthesia—Dexamethasone—psoriasis	0.000154	0.000385	CcSEcCtD
Eprosartan—Discomfort—Prednisone—psoriasis	0.000154	0.000385	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—HCAR2—psoriasis	0.000153	0.00475	CbGpPWpGaD
Eprosartan—Hypersensitivity—Prednisolone—psoriasis	0.000151	0.000378	CcSEcCtD
Eprosartan—Dyspepsia—Dexamethasone—psoriasis	0.000151	0.000377	CcSEcCtD
Eprosartan—Dyspepsia—Betamethasone—psoriasis	0.000151	0.000377	CcSEcCtD
Eprosartan—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000151	0.000377	CcSEcCtD
Eprosartan—Urticaria—Triamcinolone—psoriasis	0.00015	0.000375	CcSEcCtD
Eprosartan—Body temperature increased—Triamcinolone—psoriasis	0.000149	0.000373	CcSEcCtD
Eprosartan—Dizziness—Cyclosporine—psoriasis	0.000149	0.000373	CcSEcCtD
Eprosartan—Decreased appetite—Betamethasone—psoriasis	0.000149	0.000372	CcSEcCtD
Eprosartan—Decreased appetite—Dexamethasone—psoriasis	0.000149	0.000372	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—CCL20—psoriasis	0.000148	0.0046	CbGpPWpGaD
Eprosartan—Back pain—Methotrexate—psoriasis	0.000148	0.00037	CcSEcCtD
Eprosartan—Hypersensitivity—Hydrocortisone—psoriasis	0.000148	0.00037	CcSEcCtD
Eprosartan—Fatigue—Betamethasone—psoriasis	0.000148	0.000369	CcSEcCtD
Eprosartan—Fatigue—Dexamethasone—psoriasis	0.000148	0.000369	CcSEcCtD
Eprosartan—Shock—Prednisone—psoriasis	0.000147	0.000367	CcSEcCtD
Eprosartan—Pain—Dexamethasone—psoriasis	0.000146	0.000366	CcSEcCtD
Eprosartan—Pain—Betamethasone—psoriasis	0.000146	0.000366	CcSEcCtD
Eprosartan—Tachycardia—Prednisone—psoriasis	0.000146	0.000364	CcSEcCtD
Eprosartan—Dizziness—Mycophenolate mofetil—psoriasis	0.000146	0.000364	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000144	0.00448	CbGpPWpGaD
Eprosartan—Hyperhidrosis—Prednisone—psoriasis	0.000144	0.000361	CcSEcCtD
Eprosartan—Asthenia—Hydrocortisone—psoriasis	0.000144	0.00036	CcSEcCtD
Eprosartan—Vomiting—Cyclosporine—psoriasis	0.000143	0.000359	CcSEcCtD
Eprosartan—Rash—Cyclosporine—psoriasis	0.000142	0.000356	CcSEcCtD
Eprosartan—Anorexia—Prednisone—psoriasis	0.000142	0.000356	CcSEcCtD
Eprosartan—Dermatitis—Cyclosporine—psoriasis	0.000142	0.000355	CcSEcCtD
Eprosartan—Pruritus—Hydrocortisone—psoriasis	0.000142	0.000355	CcSEcCtD
Eprosartan—Ill-defined disorder—Methotrexate—psoriasis	0.000142	0.000355	CcSEcCtD
Eprosartan—Headache—Cyclosporine—psoriasis	0.000141	0.000354	CcSEcCtD
Eprosartan—Feeling abnormal—Dexamethasone—psoriasis	0.000141	0.000353	CcSEcCtD
Eprosartan—Feeling abnormal—Betamethasone—psoriasis	0.000141	0.000353	CcSEcCtD
Eprosartan—Gastrointestinal pain—Betamethasone—psoriasis	0.00014	0.00035	CcSEcCtD
Eprosartan—Gastrointestinal pain—Dexamethasone—psoriasis	0.00014	0.00035	CcSEcCtD
Eprosartan—Vomiting—Mycophenolate mofetil—psoriasis	0.00014	0.00035	CcSEcCtD
Eprosartan—Hypersensitivity—Triamcinolone—psoriasis	0.000139	0.000348	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000139	0.00431	CbGpPWpGaD
Eprosartan—Rash—Mycophenolate mofetil—psoriasis	0.000139	0.000347	CcSEcCtD
Eprosartan—Dermatitis—Mycophenolate mofetil—psoriasis	0.000139	0.000347	CcSEcCtD
Eprosartan—Headache—Mycophenolate mofetil—psoriasis	0.000138	0.000345	CcSEcCtD
Eprosartan—Malaise—Methotrexate—psoriasis	0.000138	0.000345	CcSEcCtD
Eprosartan—Vertigo—Methotrexate—psoriasis	0.000137	0.000343	CcSEcCtD
Eprosartan—Diarrhoea—Hydrocortisone—psoriasis	0.000137	0.000343	CcSEcCtD
Eprosartan—Urticaria—Betamethasone—psoriasis	0.000136	0.00034	CcSEcCtD
Eprosartan—Urticaria—Dexamethasone—psoriasis	0.000136	0.00034	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Prednisone—psoriasis	0.000136	0.00034	CcSEcCtD
Eprosartan—Dizziness—Prednisolone—psoriasis	0.000136	0.00034	CcSEcCtD
Eprosartan—Asthenia—Triamcinolone—psoriasis	0.000135	0.000339	CcSEcCtD
Eprosartan—Abdominal pain—Dexamethasone—psoriasis	0.000135	0.000339	CcSEcCtD
Eprosartan—Abdominal pain—Betamethasone—psoriasis	0.000135	0.000339	CcSEcCtD
Eprosartan—Body temperature increased—Dexamethasone—psoriasis	0.000135	0.000339	CcSEcCtD
Eprosartan—Body temperature increased—Betamethasone—psoriasis	0.000135	0.000339	CcSEcCtD
Eprosartan—Insomnia—Prednisone—psoriasis	0.000135	0.000338	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CCL20—psoriasis	0.000135	0.00418	CbGpPWpGaD
Eprosartan—Nausea—Cyclosporine—psoriasis	0.000134	0.000335	CcSEcCtD
Eprosartan—Paraesthesia—Prednisone—psoriasis	0.000134	0.000335	CcSEcCtD
Eprosartan—Pruritus—Triamcinolone—psoriasis	0.000134	0.000334	CcSEcCtD
Eprosartan—Cough—Methotrexate—psoriasis	0.000133	0.000333	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—TAGAP—psoriasis	0.000133	0.00412	CbGpPWpGaD
Eprosartan—Dizziness—Hydrocortisone—psoriasis	0.000133	0.000332	CcSEcCtD
Eprosartan—Dyspepsia—Prednisone—psoriasis	0.000131	0.000328	CcSEcCtD
Eprosartan—Nausea—Mycophenolate mofetil—psoriasis	0.000131	0.000327	CcSEcCtD
Eprosartan—Arthralgia—Methotrexate—psoriasis	0.00013	0.000325	CcSEcCtD
Eprosartan—Myalgia—Methotrexate—psoriasis	0.00013	0.000325	CcSEcCtD
Eprosartan—Chest pain—Methotrexate—psoriasis	0.00013	0.000325	CcSEcCtD
Eprosartan—Decreased appetite—Prednisone—psoriasis	0.00013	0.000324	CcSEcCtD
Eprosartan—Rash—Prednisolone—psoriasis	0.000129	0.000324	CcSEcCtD
Eprosartan—Dermatitis—Prednisolone—psoriasis	0.000129	0.000323	CcSEcCtD
Eprosartan—Fatigue—Prednisone—psoriasis	0.000129	0.000322	CcSEcCtD
Eprosartan—Headache—Prednisolone—psoriasis	0.000129	0.000322	CcSEcCtD
Eprosartan—Discomfort—Methotrexate—psoriasis	0.000128	0.000321	CcSEcCtD
Eprosartan—Constipation—Prednisone—psoriasis	0.000128	0.000319	CcSEcCtD
Eprosartan—Vomiting—Hydrocortisone—psoriasis	0.000127	0.000319	CcSEcCtD
Eprosartan—Rash—Hydrocortisone—psoriasis	0.000126	0.000316	CcSEcCtD
Eprosartan—Dermatitis—Hydrocortisone—psoriasis	0.000126	0.000316	CcSEcCtD
Eprosartan—Headache—Hydrocortisone—psoriasis	0.000126	0.000314	CcSEcCtD
Eprosartan—Dizziness—Triamcinolone—psoriasis	0.000125	0.000312	CcSEcCtD
Eprosartan—Feeling abnormal—Prednisone—psoriasis	0.000123	0.000308	CcSEcCtD
Eprosartan—Asthenia—Dexamethasone—psoriasis	0.000123	0.000307	CcSEcCtD
Eprosartan—Asthenia—Betamethasone—psoriasis	0.000123	0.000307	CcSEcCtD
Eprosartan—Thrombocytopenia—Methotrexate—psoriasis	0.000122	0.000305	CcSEcCtD
Eprosartan—Gastrointestinal pain—Prednisone—psoriasis	0.000122	0.000305	CcSEcCtD
Eprosartan—Nausea—Prednisolone—psoriasis	0.000122	0.000305	CcSEcCtD
Eprosartan—Pruritus—Dexamethasone—psoriasis	0.000121	0.000303	CcSEcCtD
Eprosartan—Pruritus—Betamethasone—psoriasis	0.000121	0.000303	CcSEcCtD
Eprosartan—Hyperhidrosis—Methotrexate—psoriasis	0.000121	0.000301	CcSEcCtD
Eprosartan—Vomiting—Triamcinolone—psoriasis	0.00012	0.0003	CcSEcCtD
Eprosartan—Nausea—Hydrocortisone—psoriasis	0.000119	0.000298	CcSEcCtD
Eprosartan—Rash—Triamcinolone—psoriasis	0.000119	0.000298	CcSEcCtD
Eprosartan—Dermatitis—Triamcinolone—psoriasis	0.000119	0.000297	CcSEcCtD
Eprosartan—Anorexia—Methotrexate—psoriasis	0.000119	0.000297	CcSEcCtD
Eprosartan—Urticaria—Prednisone—psoriasis	0.000118	0.000296	CcSEcCtD
Eprosartan—Headache—Triamcinolone—psoriasis	0.000118	0.000296	CcSEcCtD
Eprosartan—Abdominal pain—Prednisone—psoriasis	0.000118	0.000295	CcSEcCtD
Eprosartan—Body temperature increased—Prednisone—psoriasis	0.000118	0.000295	CcSEcCtD
Eprosartan—Diarrhoea—Dexamethasone—psoriasis	0.000117	0.000293	CcSEcCtD
Eprosartan—Diarrhoea—Betamethasone—psoriasis	0.000117	0.000293	CcSEcCtD
Eprosartan—Hypotension—Methotrexate—psoriasis	0.000116	0.000291	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000114	0.000284	CcSEcCtD
Eprosartan—Dizziness—Dexamethasone—psoriasis	0.000113	0.000283	CcSEcCtD
Eprosartan—Dizziness—Betamethasone—psoriasis	0.000113	0.000283	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	0.000113	0.00351	CbGpPWpGaD
Eprosartan—Insomnia—Methotrexate—psoriasis	0.000113	0.000282	CcSEcCtD
Eprosartan—Nausea—Triamcinolone—psoriasis	0.000112	0.000281	CcSEcCtD
Eprosartan—Paraesthesia—Methotrexate—psoriasis	0.000112	0.00028	CcSEcCtD
Eprosartan—Dyspnoea—Methotrexate—psoriasis	0.000111	0.000278	CcSEcCtD
Eprosartan—Somnolence—Methotrexate—psoriasis	0.000111	0.000277	CcSEcCtD
Eprosartan—Hypersensitivity—Prednisone—psoriasis	0.00011	0.000275	CcSEcCtD
Eprosartan—Dyspepsia—Methotrexate—psoriasis	0.00011	0.000275	CcSEcCtD
Eprosartan—Vomiting—Dexamethasone—psoriasis	0.000109	0.000272	CcSEcCtD
Eprosartan—Vomiting—Betamethasone—psoriasis	0.000109	0.000272	CcSEcCtD
Eprosartan—Decreased appetite—Methotrexate—psoriasis	0.000108	0.000271	CcSEcCtD
Eprosartan—Rash—Dexamethasone—psoriasis	0.000108	0.00027	CcSEcCtD
Eprosartan—Rash—Betamethasone—psoriasis	0.000108	0.00027	CcSEcCtD
Eprosartan—Dermatitis—Dexamethasone—psoriasis	0.000108	0.00027	CcSEcCtD
Eprosartan—Dermatitis—Betamethasone—psoriasis	0.000108	0.00027	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000108	0.00335	CbGpPWpGaD
Eprosartan—Fatigue—Methotrexate—psoriasis	0.000107	0.000269	CcSEcCtD
Eprosartan—Headache—Dexamethasone—psoriasis	0.000107	0.000268	CcSEcCtD
Eprosartan—Headache—Betamethasone—psoriasis	0.000107	0.000268	CcSEcCtD
Eprosartan—Asthenia—Prednisone—psoriasis	0.000107	0.000268	CcSEcCtD
Eprosartan—Pain—Methotrexate—psoriasis	0.000107	0.000267	CcSEcCtD
Eprosartan—Pruritus—Prednisone—psoriasis	0.000106	0.000264	CcSEcCtD
Eprosartan—Feeling abnormal—Methotrexate—psoriasis	0.000103	0.000257	CcSEcCtD
Eprosartan—Diarrhoea—Prednisone—psoriasis	0.000102	0.000255	CcSEcCtD
Eprosartan—Gastrointestinal pain—Methotrexate—psoriasis	0.000102	0.000255	CcSEcCtD
Eprosartan—Nausea—Betamethasone—psoriasis	0.000102	0.000255	CcSEcCtD
Eprosartan—Nausea—Dexamethasone—psoriasis	0.000102	0.000255	CcSEcCtD
Eprosartan—Urticaria—Methotrexate—psoriasis	9.9e-05	0.000248	CcSEcCtD
Eprosartan—Dizziness—Prednisone—psoriasis	9.86e-05	0.000247	CcSEcCtD
Eprosartan—Body temperature increased—Methotrexate—psoriasis	9.85e-05	0.000247	CcSEcCtD
Eprosartan—Abdominal pain—Methotrexate—psoriasis	9.85e-05	0.000247	CcSEcCtD
Eprosartan—Vomiting—Prednisone—psoriasis	9.48e-05	0.000237	CcSEcCtD
Eprosartan—Rash—Prednisone—psoriasis	9.4e-05	0.000235	CcSEcCtD
Eprosartan—Dermatitis—Prednisone—psoriasis	9.4e-05	0.000235	CcSEcCtD
Eprosartan—Headache—Prednisone—psoriasis	9.34e-05	0.000234	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	9.31e-05	0.00289	CbGpPWpGaD
Eprosartan—Hypersensitivity—Methotrexate—psoriasis	9.18e-05	0.00023	CcSEcCtD
Eprosartan—Asthenia—Methotrexate—psoriasis	8.94e-05	0.000224	CcSEcCtD
Eprosartan—Nausea—Prednisone—psoriasis	8.86e-05	0.000222	CcSEcCtD
Eprosartan—Pruritus—Methotrexate—psoriasis	8.82e-05	0.000221	CcSEcCtD
Eprosartan—Diarrhoea—Methotrexate—psoriasis	8.53e-05	0.000213	CcSEcCtD
Eprosartan—Dizziness—Methotrexate—psoriasis	8.24e-05	0.000206	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—CCL20—psoriasis	7.96e-05	0.00247	CbGpPWpGaD
Eprosartan—Vomiting—Methotrexate—psoriasis	7.93e-05	0.000198	CcSEcCtD
Eprosartan—Rash—Methotrexate—psoriasis	7.86e-05	0.000197	CcSEcCtD
Eprosartan—Dermatitis—Methotrexate—psoriasis	7.85e-05	0.000196	CcSEcCtD
Eprosartan—Headache—Methotrexate—psoriasis	7.81e-05	0.000195	CcSEcCtD
Eprosartan—Nausea—Methotrexate—psoriasis	7.4e-05	0.000185	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CXCL8—psoriasis	7.09e-05	0.0022	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	7.06e-05	0.00219	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NDUFA5—psoriasis	5.34e-05	0.00166	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.98e-05	0.00155	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2S1—psoriasis	4.54e-05	0.00141	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SOCS1—psoriasis	4.38e-05	0.00136	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—TYK2—psoriasis	4.18e-05	0.0013	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—psoriasis	4e-05	0.00124	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—psoriasis	3.64e-05	0.00113	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LEP—psoriasis	3.23e-05	0.001	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APOE—psoriasis	3.23e-05	0.001	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NFKBIA—psoriasis	3.01e-05	0.000935	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TYK2—psoriasis	2.47e-05	0.000766	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.38e-05	0.000739	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CARM1—psoriasis	2.22e-05	0.000688	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—psoriasis	2.15e-05	0.000667	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.07e-05	0.000643	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—psoriasis	2.04e-05	0.000634	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JUN—psoriasis	2e-05	0.00062	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NFKB1—psoriasis	1.92e-05	0.000597	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—psoriasis	1.74e-05	0.000541	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—psoriasis	1.73e-05	0.000536	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CAT—psoriasis	1.36e-05	0.000423	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—psoriasis	1.32e-05	0.000409	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—psoriasis	1.21e-05	0.000374	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APOE—psoriasis	1.06e-05	0.000329	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARG—psoriasis	9.23e-06	0.000287	CbGpPWpGaD
